The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens

被引：41
作者：
MacGowan, A [1 ]
Rogers, C
Bowker, K
机构：
[1] N Bristol NHS Trust, Bristol Ctr Antimicrobial Res & Evaluat, Bristol BS10 5NB, Avon, England
[2] Univ Bristol, Dept Med Microbiol, Southmead Hosp, Bristol BS10 5NB, Avon, England
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2000年 / 46卷 / 02期
关键词：
D O I：
10.1093/jac/46.2.163
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
[No abstract available]
引用
收藏
页码：163 / 170
页数：8
相关论文
共 49 条
  • [1] AESCHLIMANN JR, 1998, 38 INT C ANT AG CHEM, P12
  • [2] QUESTIONING DOSING REGIMENS OF CIPROFLOXACIN
    BAUERNFEIND, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (05) : 789 - 798
  • [3] Bauernfeind A., 1999, Journal of Antimicrobial Chemotherapy, V43, P77, DOI 10.1093/jac/43.suppl_3.77
  • [4] BAUERNFEIND A, 1994, CIPROFLOXACIN 1, V5, P37
  • [5] BAUERNFEIND A, 1998, ANTIINFECTIVE DR S71, V16, pT135
  • [6] COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE
    BLASER, J
    STONE, BB
    GRONER, MC
    ZINNER, SH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) : 1054 - 1060
  • [7] IN-VIVO VERIFICATION OF IN-VITRO MODEL OF ANTIBIOTIC-TREATMENT OF DEVICE-RELATED INFECTION
    BLASER, J
    VERGERES, P
    WIDMER, AF
    ZIMMERLI, W
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) : 1134 - 1139
  • [8] Bowker Karen E., 1999, Journal of Antimicrobial Chemotherapy, V44, P58
  • [9] Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin
    Bowker, KE
    Wootton, M
    Rogers, CA
    Lewis, R
    Holt, HA
    MacGowan, AP
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) : 661 - 667
  • [10] BOWKER KE, 1998, 38 INT C ANT AG CHEM, P229
12345